BioMarin Pharmaceutical Inc. (BMRN)
Automate Your Wheel Strategy on BMRN
With Tiblio's Option Bot, you can configure your own wheel strategy including BMRN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMRN
- Rev/Share 15.3836
- Book/Share 30.3375
- PB 1.9141
- Debt/Equity 0.1028
- CurrentRatio 5.5203
- ROIC 0.0718
- MktCap 11136432320.0
- FreeCF/Share 3.2476
- PFCF 17.9567
- PE 21.1678
- Debt/Assets 0.0833
- DivYield 0
- ROE 0.0946
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | BMRN | Oppenheimer | Perform | Outperform | -- | $98 | Feb. 24, 2025 |
| Resumed | BMRN | Raymond James | -- | Outperform | -- | $79 | Oct. 10, 2024 |
| Upgrade | BMRN | Bernstein | Market Perform | Outperform | $94 | $110 | Aug. 20, 2024 |
News
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
Read More
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Published: May 16, 2025 by: PRNewsWire
Sentiment: Neutral
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif.
Read More
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral
New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function Data from the largest retrospective, multi-year observational study of more than 600 children and adults with hypochondroplasia found significantly higher rates of comorbidities, surgeries and overall doctor visits SAN RAFAEL, Calif. , May 12, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from studies of VOXZOGO ® (vosoritide), demonstrating meaningful impact on tibial bowing in children with achondroplasia and investigational early efficacy results in other skeletal conditions.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
BioMarin's First-Quarter Earnings & Sales Beat Estimates
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
Published: April 17, 2025 by: PRNewsWire
Sentiment: Neutral
SAN RAFAEL, Calif. , April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m.
Read More
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Read More
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Read More
What Makes BioMarin (BMRN) a New Buy Stock
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
Read More
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
5 Historically Cheap Growth Stocks to Buy With Confidence in the Wake of the Nasdaq Correction
Published: March 27, 2025 by: The Motley Fool
Sentiment: Positive
Every so often, Wall Street sends a not-so-subtle reminder to investors that stocks can move in both directions.
Read More
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
Read More
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
New data also to be presented for PALYNZIQ® (pegvaliaise-pqpz), reinforcing its value in sustaining blood Phe level reduction and improving health-related quality of life for adults with phenylketonuria SAN RAFAEL, Calif. , March 20, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive new data from studies of VOXZOGO ® (vosoritide) in children with achondroplasia and in ongoing clinical trials investigating other skeletal conditions, as well as PALYNZIQ ® (pegvaliase-pqpz) in adults with phenylketonuria (PKU).
Read More
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Buy These 5 Top-Ranked Stocks to Play Likely Earnings Beat
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Top-ranked stocks Doximity (DOCS), Life Time Group Holdings (LTH), Adtalem Global Education (ATGE), BioMarin Pharmaceutical (BMRN) and Iridium Communications (IRDM) are likely to beat on the bottom line in their upcoming releases.
Read More
4 Discounted PEG Stocks Offering the Best Returns to Value Investors
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Here we present four discounted PEG stocks that qualify our screening criteria, TAP, BMRN, DVN and JAZZ.
Read More
Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
BOOT, STRL, DECK & BMRN's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
About BioMarin Pharmaceutical Inc. (BMRN)
- IPO Date 1999-07-26
- Website https://www.biomarin.com
- Industry Biotechnology
- CEO Mr. Alexander Hardy
- Employees 3040